MedTrace Logo

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

NCT05198245 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2026-01-08

No results posted yet for this study

Summary

The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.

Conditions

Interventions

DRUG

Rimegepant

Rimegepant 75mg

DRUG

Various

Various

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • RTI Health Solutions

    collaborator OTHER

  • Optum, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
16 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2028-04-17
Completion
2028-04-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05198245 on ClinicalTrials.gov